Mersana Therapeutics (MRSN) Scheduled to Post Quarterly Earnings on Wednesday

Share on StockTwits

Mersana Therapeutics (NASDAQ:MRSN) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, August 15th. Analysts expect the company to announce earnings of ($0.58) per share for the quarter.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings data on Monday, May 14th. The company reported ($0.54) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.07. The business had revenue of $3.06 million during the quarter, compared to analyst estimates of $3.49 million. Mersana Therapeutics had a negative return on equity of 124.32% and a negative net margin of 263.80%. On average, analysts expect Mersana Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Shares of Mersana Therapeutics opened at $12.87 on Monday, reports. The firm has a market capitalization of $288.56 million, a PE ratio of -4.00 and a beta of -2.34. Mersana Therapeutics has a fifty-two week low of $8.76 and a fifty-two week high of $23.96.

In other news, insider Timothy B. Lowinger sold 3,500 shares of the company’s stock in a transaction on Monday, July 23rd. The stock was sold at an average price of $11.06, for a total transaction of $38,710.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 39.70% of the company’s stock.

MRSN has been the subject of several research analyst reports. Cowen restated a “buy” rating on shares of Mersana Therapeutics in a report on Monday, April 16th. HC Wainwright set a $33.00 price objective on Mersana Therapeutics and gave the company a “buy” rating in a report on Tuesday, May 15th. ValuEngine lowered Mersana Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, July 16th. Zacks Investment Research lowered Mersana Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 25th. Finally, Leerink Swann lowered Mersana Therapeutics from an “outperform” rating to a “market perform” rating and set a $61.00 price objective for the company. in a report on Thursday, July 19th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $29.60.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability.

Featured Article: Leveraged Buyout (LBO) Explained

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply